Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Poulam M Patel

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaAlexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trialAlexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Oncoimmunology|June 7, 2018
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trialPoulam M Patel, Christian H Ottensmeier, Clive Mulatero, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Poulam M Patel, Stefan Suciu, Laurent Mortier, et al.
Pigment Cell & Melanoma Research|August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeuticsJason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuriesStuart Astbury, Edmond Atallah, Jane I Grove, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeJan Bogaerts, Matthew R Sydes, Nicola Keat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2023
Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell CarcinomaNaveen S Vasudev, Ghislaine Scelo, Kate I Glennon, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaAlexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trialAlexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Oncoimmunology|June 7, 2018
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trialPoulam M Patel, Christian H Ottensmeier, Clive Mulatero, et al.
The Lancet. Oncology|February 4, 2014
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsKeith T Flaherty, Michael Hennig, Sandra J Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2011
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Poulam M Patel, Stefan Suciu, Laurent Mortier, et al.
Pigment Cell & Melanoma Research|August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeuticsJason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuriesStuart Astbury, Edmond Atallah, Jane I Grove, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeJan Bogaerts, Matthew R Sydes, Nicola Keat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2023
Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell CarcinomaNaveen S Vasudev, Ghislaine Scelo, Kate I Glennon, et al.
Pageof 4